We’re also continuing to track the fallout from all the recent FDA controversies.

In this edition of STAT's Health Tech newsletter: the latest on GLP-1 microdosing, AI for medical coding and more.

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Fewer pre-teens and adolescents are vaping nicotine these days than in previous years. But a study published yesterday in ...

Sarepta Therapeutics delivered a disastrous third-quarter earnings performance. A long-delayed confirmatory clinical trial of ...

It was the latest shockwave to sweep through an agency beset by all kinds of tumult in recent months. In interviews, ...

Compass Pathways, which is developing a psilocybin treatment for severe depression, said it now expects an earlier decision ...

Sobriety didn’t restore the old version of me; it allowed me to build a new one from the driftwood of the past,” ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement ...

Metsera said Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer valuing the company for up to $10 billion.

The findings are similar to an analysis STAT conducted, and raise questions about why UnitedHealth pays its doctors more.